Computational Biology Market Size by Application, Services, End Use, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2029
19.93%
CAGR (2023-2029)
4.3 USD Bn.
Market Size
327
Report Pages
149
Market Tables
Overview
Computational Biology Market was valued at US$ 4.30 Bn in 2022 and is expected to reach US$ 15.36 Bn by 2029, at a CAGR of 19.93% during a forecast period.
The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region.
To know about the Research Methodology:-Request Free Sample Report
Dynamics:
The global computational biology market has witnessed significant growth in recent years because of its assistance in the field of biotechnology and medicine. Combing biology and computers, computational biology helps in drug breakthroughs and consequent development during the several stages of clinical trials. The wide use of computational biology in biotechnology and pharmaceuticals driving the market.
Lack of innovative drugs and increasing drug failures in later stages of development had taken its toll on the pharmaceutical industry, amounting to huge financial losses. However, adopting computational biology above a period of time has led to not just minimized clinical stage expenditure but also decreased the frequency of drug failures. This has mainly driven the computational biology market. Additionally, enhanced government funding and industrial support, as well as improved computational tools have driven the growth of the industry. The use of computational biology in modelling and simulation of pediatrics drug development is expected to open various doors for future expansion.
Cellular and biological simulation segment is expected to continue leading with over 34.0% market share by 2029. Computational cell modelling and biological simulation aid decipher the biological and physiological functions of cells. Increased unmet medical desires and burgeoning demand for personalized medicine are expected to shape the future growth of the application segment.
Commercial led the end use segment in 2022, attributed to the rise in the bioinformatics research, drug designing, and usage in personalized medicine. Such as, in August 2021, the European Union and India’s Department of Biotechnology (DBT) announced the fund of US$ 17.2 Mn towards research and innovation for the development of next-generation influenza virus to protect individuals worldwide.
Computational Biology Market Regional Insights:
North America is expected to contribute to the largest market share in the computational biology market in the coming years, because of increasing investments made in R&D activities for the discovery as well as the development of novel drugs. Also, the Asia Pacific is anticipated to witness steady growth during the forecast period, owing to increasing clinical trials in the region.
In Feb 2021, StemoniX Inc., the USA based provider of product and services for drug discovery and development, received funding of US$ 14.40 Mn from a group of investors. Brightstone Venture Capital was the major financer and was later combined by Crescent Ridge Partners, Alumni Ventures Group, and Mayo Clinic.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Computational Biology Market dynamics, structure by identifying and analyzing the market segments and project the global market size.
Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global Computational Biology Market.
Computational Biology Market Key Highlights:
Global Computational Biology Market analysis and forecast, in terms of value.
Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Computational Biology Market
Global Computational Biology Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided.
The Global Computational Biology Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study.
Global Computational Biology Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation.
Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled.
Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Computational Biology Market are also profiled.
Computational Biology Market Scope: Inquire before buying
| Computational Biology Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2022 | Forecast Period: | 2023-2029 |
| Historical Data: | 2018 to 2022 | Market Size in 2022: | US $ 4.30 Bn. |
| Forecast Period 2023 to 2029 CAGR: | 19.93% | Market Size in 2029: | US $ 15.36 Bn. |
| Segments Covered: | by Application | Cellular & Biological Simulation Computational Genomics 1.Databases 2.Infrastructure/Hardware 3.Software & Services Computational Proteomics Pharmacogenomics Others (Transcriptomics/ Metabolomics) Drug Discovery & Disease Modelling Target Identification Target Validation Lead Discovery Lead Optimization Preclinical Drug Development Pharmacokinetic Pharmacodynamics Clinical Trials Phase I The Phase II Phase III Human Body Simulation Software |
|
| by Services | In-house Contract |
||
| by End Use | Academics Industry Commercial |
||
by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Computational Biology Market Key Player:
1. DassaultSystèmes SE
2. Certara
3. Chemical Computing Group ULC
4. Compugen Ltd
5. Rosa & Co. LLC
6. Genedata AG
7. Insilico Biotechnology AG
8. Leadscope Inc.
9. Nimbus Discovery LLC
10.Strand Life Sciences
11.Schrodinger
12.Simulation Plus Inc.
13.Accelrys
14.Entelos
15.RhenoviaPharma Sa
16.StemoniXInc
17.Computational Genomics Laboratory
18.Elucidata
19.DNAnexus
20.Simons Foundation
Frequently Asked Questions:
1. Which region has the largest share in Global Computational Biology Market?
Ans: North America region held the highest share in 2022.
2. What is the growth rate of Global Computational Biology Market?
Ans: The Global Computational Biology Market is growing at a CAGR of 19.93% during forecasting period 2023-2029.
3. What is scope of the Global Computational Biology market report?
Ans: Global market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Computational Biology market?
Ans: The important key players in the global market are – DassaultSystèmes SE, Certara, Chemical Computing Group ULC, Compugen Ltd, Rosa & Co. LLC, Genedata AG, Insilico Biotechnology AG, Leadscope Inc., Nimbus Discovery LLC, Strand Life Sciences, Schrodinger, Simulation Plus Inc., Accelrys, Entelos, RhenoviaPharma Sa, StemoniXInc, Computational Genomics Laboratory, Elucidata, DNAnexus, and Simons Foundation
5. What is the study period of this market?
Ans: The Global Computational Biology Market is studied from 2022 to 2029.
Table of Contents
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives
2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary : Global Computational Biology Market Size, by Market Value (US$ Bn)
4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends in Global Computational Biology Market
5. Supply Side and Demand Side Indicators
6. Global Computational Biology Market Analysis and Forecast
6.1. Global Computational Biology Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America
7. Global Computational Biology Market Analysis and Forecast, by Services
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Computational Biology Market Value Share Analysis, by Services
7.4. Global Computational Biology Market Size (US$ Bn) Forecast, by Services
7.5. Global Computational Biology Market Analysis, by Services
7.6. Global Computational Biology Market Attractiveness Analysis, by Services
8. Global Computational Biology Market Analysis and Forecast, by Application
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Computational Biology Market Value Share Analysis, by Application
8.4. Global Computational Biology Market Size (US$ Bn) Forecast, by Application
8.5. Global Computational Biology Market Analysis, by Application
8.6. Global Computational Biology Market Attractiveness Analysis, by Application
9. Global Computational Biology Market Analysis and Forecast, by End Use
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Computational Biology Market Value Share Analysis, by End Use
9.4. Global Computational Biology Market Size (US$ Bn) Forecast, by End Use
9.5. Global Computational Biology Market Analysis, by End Use
9.6. Global Computational Biology Market Attractiveness Analysis, by End Use
10. Global Computational Biology Market Analysis, by Region
10.1. Global Computational Biology Market Value Share Analysis, by Region
10.2. Global Computational Biology Market Size (US$ Bn) Forecast, by Region
10.3. Global Computational Biology Market Attractiveness Analysis, by Region
11. North America Computational Biology Market Analysis
11.1. Key Findings
11.2. North America Computational Biology Market Overview
11.3. North America Computational Biology Market Value Share Analysis, by Services
11.4. North America Computational Biology Market Forecast, by Services
11.4.1. In-house
11.4.2. Contract
11.5. North America Computational Biology Market Value Share Analysis, by Application
11.6. North America Computational Biology Market Forecast, by Application
11.6.1. Cellular & Biological Simulation
11.6.1.1. Computational Genomics
11.6.1.1.1. Databases
11.6.1.1.2. Infrastructure/Hardware
11.6.1.1.3. Software & Services
11.6.1.2. Computational Proteomics
11.6.1.3. Pharmacogenomics
11.6.1.4. Others (Transcriptomics/ Metabolomics)
11.6.2. Drug Discovery & Disease Modelling
11.6.2.1. Target Identification
11.6.2.2. Target Validation
11.6.2.3. Lead Discovery
11.6.2.4. Lead Optimization
11.6.3. Preclinical Drug Development
11.6.3.1. Pharmacokinetic
11.6.3.2. Pharmacodynamics
11.6.4. Clinical Trials
11.6.4.1. Phase I
11.6.4.2. Phase II
11.6.4.3. Phase III
11.6.5. Human Body Simulation Software
11.7. North America Computational Biology Market Value Share Analysis, by End Use
11.8. North America Computational Biology Market Forecast, by End Use
11.8.1. Academics
11.8.2. Industry
11.8.3. Commercial
11.9. North America Computational Biology Market Value Share Analysis, by Country
11.10. North America Computational Biology Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Computational Biology Market Analysis, by Country
11.12. U.S. Computational Biology Market Forecast, by Services
11.12.1. In-house
11.12.2. Contract
11.13. U.S. Computational Biology Market Forecast, by Application
11.13.1. Cellular & Biological Simulation
11.13.1.1. Computational Genomics
11.13.1.1.1. Databases
11.13.1.1.2. Infrastructure/Hardware
11.13.1.1.3. Software & Services
11.13.1.2. Computational Proteomics
11.13.1.3. Pharmacogenomics
11.13.1.4. Others (Transcriptomics/ Metabolomics)
11.13.2. Drug Discovery & Disease Modelling
11.13.2.1. Target Identification
11.13.2.2. Target Validation
11.13.2.3. Lead Discovery
11.13.2.4. Lead Optimization
11.13.3. Preclinical Drug Development
11.13.3.1. Pharmacokinetic
11.13.3.2. Pharmacodynamics
11.13.4. Clinical Trials
11.13.4.1. Phase I
11.13.4.2. Phase II
11.13.4.3. Phase III
11.13.5. Human Body Simulation Software
11.14. U.S. Computational Biology Market Forecast, by End Use
11.14.1. Academics
11.14.2. Industry
11.14.3. Commercial
11.15. Canada Computational Biology Market Forecast, by Services
11.15.1. In-house
11.15.2. Contract
11.16. Canada Computational Biology Market Forecast, by Application
11.16.1. Cellular & Biological Simulation
11.16.1.1. Computational Genomics
11.16.1.1.1. Databases
11.16.1.1.2. Infrastructure/Hardware
11.16.1.1.3. Software & Services
11.16.1.2. Computational Proteomics
11.16.1.3. Pharmacogenomics
11.16.1.4. Others (Transcriptomics/ Metabolomics)
11.16.2. Drug Discovery & Disease Modelling
11.16.2.1. Target Identification
11.16.2.2. Target Validation
11.16.2.3. Lead Discovery
11.16.2.4. Lead Optimization
11.16.3. Preclinical Drug Development
11.16.3.1. Pharmacokinetic
11.16.3.2. Pharmacodynamics
11.16.4. Clinical Trials
11.16.4.1. Phase I
11.16.4.2. Phase II
11.16.4.3. Phase III
11.16.5. Human Body Simulation Software
11.17. Canada Computational Biology Market Forecast, by End Use
11.17.1. Academics
11.17.2. Industry
11.17.3. Commercial
11.18. North America Computational Biology Market Attractiveness Analysis
11.18.1. By Services
11.18.2. By Application
11.18.3. By End Use
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments
12. Europe Computational Biology Market Analysis
12.1. Key Findings
12.2. Europe Computational Biology Market Overview
12.3. Europe Computational Biology Market Value Share Analysis, by Services
12.4. Europe Computational Biology Market Forecast, by Services
12.4.1. In-house
12.4.2. Contract
12.5. Europe Computational Biology Market Value Share Analysis, by Application
12.6. Europe Computational Biology Market Forecast, by Application
12.6.1. Cellular & Biological Simulation
12.6.1.1. Computational Genomics
12.6.1.1.1. Databases
12.6.1.1.2. Infrastructure/Hardware
12.6.1.1.3. Software & Services
12.6.1.2. Computational Proteomics
12.6.1.3. Pharmacogenomics
12.6.1.4. Others (Transcriptomics/ Metabolomics)
12.6.2. Drug Discovery & Disease Modelling
12.6.2.1. Target Identification
12.6.2.2. Target Validation
12.6.2.3. Lead Discovery
12.6.2.4. Lead Optimization
12.6.3. Preclinical Drug Development
12.6.3.1. Pharmacokinetic
12.6.3.2. Pharmacodynamics
12.6.4. Clinical Trials
12.6.4.1. Phase I
12.6.4.2. Phase II
12.6.4.3. Phase III
12.6.5. Human Body Simulation Software
12.7. Europe Computational Biology Market Value Share Analysis, by End Use
12.8. Europe Computational Biology Market Forecast, by End Use
12.8.1. Academics
12.8.2. Industry
12.8.3. Commercial
12.9. Europe Computational Biology Market Value Share Analysis, by Country
12.10. Europe Computational Biology Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Computational Biology Market Analysis, by Country
12.12. Germany Computational Biology Market Forecast, by Services
12.12.1. In-house
12.12.2. Contract
12.13. Germany Computational Biology Market Forecast, by Application
12.13.1. Cellular & Biological Simulation
12.13.1.1. Computational Genomics
12.13.1.1.1. Databases
12.13.1.1.2. Infrastructure/Hardware
12.13.1.1.3. Software & Services
12.13.1.2. Computational Proteomics
12.13.1.3. Pharmacogenomics
12.13.1.4. Others (Transcriptomics/ Metabolomics)
12.13.2. Drug Discovery & Disease Modelling
12.13.2.1. Target Identification
12.13.2.2. Target Validation
12.13.2.3. Lead Discovery
12.13.2.4. Lead Optimization
12.13.3. Preclinical Drug Development
12.13.3.1. Pharmacokinetic
12.13.3.2. Pharmacodynamics
12.13.4. Clinical Trials
12.13.4.1. Phase I
12.13.4.2. Phase II
12.13.4.3. Phase III
12.13.5. Human Body Simulation Software
12.14. Germany Computational Biology Market Forecast, by End Use
12.14.1. Academics
12.14.2. Industry
12.14.3. Commercial
12.15. U.K. Computational Biology Market Forecast, by Services
12.15.1. In-house
12.15.2. Contract
12.16. U.K. Computational Biology Market Forecast, by Application
12.16.1. Cellular & Biological Simulation
12.16.1.1. Computational Genomics
12.16.1.1.1. Databases
12.16.1.1.2. Infrastructure/Hardware
12.16.1.1.3. Software & Services
12.16.1.2. Computational Proteomics
12.16.1.3. Pharmacogenomics
12.16.1.4. Others (Transcriptomics/ Metabolomics)
12.16.2. Drug Discovery & Disease Modelling
12.16.2.1. Target Identification
12.16.2.2. Target Validation
12.16.2.3. Lead Discovery
12.16.2.4. Lead Optimization
12.16.3. Preclinical Drug Development
12.16.3.1. Pharmacokinetic
12.16.3.2. Pharmacodynamics
12.16.4. Clinical Trials
12.16.4.1. Phase I
12.16.4.2. Phase II
12.16.4.3. Phase III
12.16.5. Human Body Simulation Software
12.17. U.K. Computational Biology Market Forecast, by End Use
12.17.1. Academics
12.17.2. Industry
12.17.3. Commercial
12.18. France Computational Biology Market Forecast, by Services
12.18.1. In-house
12.18.2. Contract
12.19. France Computational Biology Market Forecast, by Application
12.19.1. Cellular & Biological Simulation
12.19.1.1. Computational Genomics
12.19.1.1.1. Databases
12.19.1.1.2. Infrastructure/Hardware
12.19.1.1.3. Software & Services
12.19.1.2. Computational Proteomics
12.19.1.3. Pharmacogenomics
12.19.1.4. Others (Transcriptomics/ Metabolomics)
12.19.2. Drug Discovery & Disease Modelling
12.19.2.1. Target Identification
12.19.2.2. Target Validation
12.19.2.3. Lead Discovery
12.19.2.4. Lead Optimization
12.19.3. Preclinical Drug Development
12.19.3.1. Pharmacokinetic
12.19.3.2. Pharmacodynamics
12.19.4. Clinical Trials
12.19.4.1. Phase I
12.19.4.2. Phase II
12.19.4.3. Phase III
12.19.5. Human Body Simulation Software
12.20. France Computational Biology Market Forecast, by End Use
12.20.1. Academics
12.20.2. Industry
12.20.3. Commercial
12.21. Italy Computational Biology Market Forecast, by Services
12.21.1. In-house
12.21.2. Contract
12.22. Italy Computational Biology Market Forecast, by Application
12.22.1. Cellular & Biological Simulation
12.22.1.1. Computational Genomics
12.22.1.1.1. Databases
12.22.1.1.2. Infrastructure/Hardware
12.22.1.1.3. Software & Services
12.22.1.2. Computational Proteomics
12.22.1.3. Pharmacogenomics
12.22.1.4. Others (Transcriptomics/ Metabolomics)
12.22.2. Drug Discovery & Disease Modelling
12.22.2.1. Target Identification
12.22.2.2. Target Validation
12.22.2.3. Lead Discovery
12.22.2.4. Lead Optimization
12.22.3. Preclinical Drug Development
12.22.3.1. Pharmacokinetic
12.22.3.2. Pharmacodynamics
12.22.4. Clinical Trials
12.22.4.1. Phase I
12.22.4.2. Phase II
12.22.4.3. Phase III
12.22.5. Human Body Simulation Software
12.23. Italy Computational Biology Market Forecast, by End Use
12.23.1. Academics
12.23.2. Industry
12.23.3. Commercial
12.24. Spain Computational Biology Market Forecast, by Services
12.24.1. In-house
12.24.2. Contract
12.25. Spain Computational Biology Market Forecast, by Application
12.25.1. Cellular & Biological Simulation
12.25.1.1. Computational Genomics
12.25.1.1.1. Databases
12.25.1.1.2. Infrastructure/Hardware
12.25.1.1.3. Software & Services
12.25.1.2. Computational Proteomics
12.25.1.3. Pharmacogenomics
12.25.1.4. Others (Transcriptomics/ Metabolomics)
12.25.2. Drug Discovery & Disease Modelling
12.25.2.1. Target Identification
12.25.2.2. Target Validation
12.25.2.3. Lead Discovery
12.25.2.4. Lead Optimization
12.25.3. Preclinical Drug Development
12.25.3.1. Pharmacokinetic
12.25.3.2. Pharmacodynamics
12.25.4. Clinical Trials
12.25.4.1. Phase I
12.25.4.2. Phase II
12.25.4.3. Phase III
12.25.5. Human Body Simulation Software
12.26. Spain Computational Biology Market Forecast, by End Use
12.26.1. Academics
12.26.2. Industry
12.26.3. Commercial
12.27. Rest of Europe Computational Biology Market Forecast, by Services
12.27.1. In-house
12.27.2. Contract
12.28. Rest of Europe Computational Biology Market Forecast, by Application
12.28.1. Cellular & Biological Simulation
12.28.1.1. Computational Genomics
12.28.1.1.1. Databases
12.28.1.1.2. Infrastructure/Hardware
12.28.1.1.3. Software & Services
12.28.1.2. Computational Proteomics
12.28.1.3. Pharmacogenomics
12.28.1.4. Others (Transcriptomics/ Metabolomics)
12.28.2. Drug Discovery & Disease Modelling
12.28.2.1. Target Identification
12.28.2.2. Target Validation
12.28.2.3. Lead Discovery
12.28.2.4. Lead Optimization
12.28.3. Preclinical Drug Development
12.28.3.1. Pharmacokinetic
12.28.3.2. Pharmacodynamics
12.28.4. Clinical Trials
12.28.4.1. Phase I
12.28.4.2. Phase II
12.28.4.3. Phase III
12.28.5. Human Body Simulation Software
12.29. Rest Of Europe Computational Biology Market Forecast, by End Use
12.29.1. Academics
12.29.2. Industry
12.29.3. Commercial
12.30. Europe Computational Biology Market Attractiveness Analysis
12.30.1. By Services
12.30.2. By Application
12.30.3. By End Use
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments
13. Asia Pacific Computational Biology Market Analysis
13.1. Key Findings
13.2. Asia Pacific Computational Biology Market Overview
13.3. Asia Pacific Computational Biology Market Value Share Analysis, by Services
13.4. Asia Pacific Computational Biology Market Forecast, by Services
13.4.1. In-house
13.4.2. Contract
13.5. Asia Pacific Computational Biology Market Value Share Analysis, by Application
13.6. Asia Pacific Computational Biology Market Forecast, by Application
13.6.1. Cellular & Biological Simulation
13.6.1.1. Computational Genomics
13.6.1.1.1. Databases
13.6.1.1.2. Infrastructure/Hardware
13.6.1.1.3. Software & Services
13.6.1.2. Computational Proteomics
13.6.1.3. Pharmacogenomics
13.6.1.4. Others (Transcriptomics/ Metabolomics)
13.6.2. Drug Discovery & Disease Modelling
13.6.2.1. Target Identification
13.6.2.2. Target Validation
13.6.2.3. Lead Discovery
13.6.2.4. Lead Optimization
13.6.3. Preclinical Drug Development
13.6.3.1. Pharmacokinetic
13.6.3.2. Pharmacodynamics
13.6.4. Clinical Trials
13.6.4.1. Phase I
13.6.4.2. Phase II
13.6.4.3. Phase III
13.6.5. Human Body Simulation Software
13.7. Asia Pacific Computational Biology Market Value Share Analysis, by End Use
13.8. Asia Pacific Computational Biology Market Forecast, by End Use
13.8.1. Academics
13.8.2. Industry
13.8.3. Commercial
13.9. Asia Pacific Computational Biology Market Value Share Analysis, by Country
13.10. Asia Pacific Computational Biology Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Computational Biology Market Analysis, by Country
13.12. China Computational Biology Market Forecast, by Services
13.12.1. In-house
13.12.2. Contract
13.13. China Computational Biology Market Forecast, by Application
13.13.1. Cellular & Biological Simulation
13.13.1.1. Computational Genomics
13.13.1.1.1. Databases
13.13.1.1.2. Infrastructure/Hardware
13.13.1.1.3. Software & Services
13.13.1.2. Computational Proteomics
13.13.1.3. Pharmacogenomics
13.13.1.4. Others (Transcriptomics/ Metabolomics)
13.13.2. Drug Discovery & Disease Modelling
13.13.2.1. Target Identification
13.13.2.2. Target Validation
13.13.2.3. Lead Discovery
13.13.2.4. Lead Optimization
13.13.3. Preclinical Drug Development
13.13.3.1. Pharmacokinetic
13.13.3.2. Pharmacodynamics
13.13.4. Clinical Trials
13.13.4.1. Phase I
13.13.4.2. Phase II
13.13.4.3. Phase III
13.13.5. Human Body Simulation Software
13.14. China Computational Biology Market Forecast, by End Use
13.14.1. Academics
13.14.2. Industry
13.14.3. Commercial
13.15. India Computational Biology Market Forecast, by Services
13.15.1. In-house
13.15.2. Contract
13.16. India Computational Biology Market Forecast, by Application
13.16.1. Cellular & Biological Simulation
13.16.1.1. Computational Genomics
13.16.1.1.1. Databases
13.16.1.1.2. Infrastructure/Hardware
13.16.1.1.3. Software & Services
13.16.1.2. Computational Proteomics
13.16.1.3. Pharmacogenomics
13.16.1.4. Others (Transcriptomics/ Metabolomics)
13.16.2. Drug Discovery & Disease Modelling
13.16.2.1. Target Identification
13.16.2.2. Target Validation
13.16.2.3. Lead Discovery
13.16.2.4. Lead Optimization
13.16.3. Preclinical Drug Development
13.16.3.1. Pharmacokinetic
13.16.3.2. Pharmacodynamics
13.16.4. Clinical Trials
13.16.4.1. Phase I
13.16.4.2. Phase II
13.16.4.3. Phase III
13.16.5. Human Body Simulation Software
13.17. India Computational Biology Market Forecast, by End Use
13.17.1. Academics
13.17.2. Industry
13.17.3. Commercial
13.18. Japan Computational Biology Market Forecast, by Services
13.18.1. In-house
13.18.2. Contract
13.19. Japan Computational Biology Market Forecast, by Application
13.19.1. Cellular & Biological Simulation
13.19.1.1. Computational Genomics
13.19.1.1.1. Databases
13.19.1.1.2. Infrastructure/Hardware
13.19.1.1.3. Software & Services
13.19.1.2. Computational Proteomics
13.19.1.3. Pharmacogenomics
13.19.1.4. Others (Transcriptomics/ Metabolomics)
13.19.2. Drug Discovery & Disease Modelling
13.19.2.1. Target Identification
13.19.2.2. Target Validation
13.19.2.3. Lead Discovery
13.19.2.4. Lead Optimization
13.19.3. Preclinical Drug Development
13.19.3.1. Pharmacokinetic
13.19.3.2. Pharmacodynamics
13.19.4. Clinical Trials
13.19.4.1. Phase I
13.19.4.2. Phase II
13.19.4.3. Phase III
13.19.5. Human Body Simulation Software
13.20. Japan Computational Biology Market Forecast, by End Use
13.20.1. Academics
13.20.2. Industry
13.20.3. Commercial
13.21. ASEAN Computational Biology Market Forecast, by Services
13.21.1. In-house
13.21.2. Contract
13.22. ASEAN Computational Biology Market Forecast, by Application
13.22.1. Cellular & Biological Simulation
13.22.1.1. Computational Genomics
13.22.1.1.1. Databases
13.22.1.1.2. Infrastructure/Hardware
13.22.1.1.3. Software & Services
13.22.1.2. Computational Proteomics
13.22.1.3. Pharmacogenomics
13.22.1.4. Others (Transcriptomics/ Metabolomics)
13.22.2. Drug Discovery & Disease Modelling
13.22.2.1. Target Identification
13.22.2.2. Target Validation
13.22.2.3. Lead Discovery
13.22.2.4. Lead Optimization
13.22.3. Preclinical Drug Development
13.22.3.1. Pharmacokinetic
13.22.3.2. Pharmacodynamics
13.22.4. Clinical Trials
13.22.4.1. Phase I
13.22.4.2. Phase II
13.22.4.3. Phase III
13.22.5. Human Body Simulation Software
13.23. ASEAN Computational Biology Market Forecast, by End Use
13.23.1. Academics
13.23.2. Industry
13.23.3. Commercial
13.24. Rest of Asia Pacific Computational Biology Market Forecast, by Services
13.24.1. In-house
13.24.2. Contract
13.25. Rest of Asia Pacific Computational Biology Market Forecast, by Application
13.25.1. Cellular & Biological Simulation
13.25.1.1. Computational Genomics
13.25.1.1.1. Databases
13.25.1.1.2. Infrastructure/Hardware
13.25.1.1.3. Software & Services
13.25.1.2. Computational Proteomics
13.25.1.3. Pharmacogenomics
13.25.1.4. Others (Transcriptomics/ Metabolomics)
13.25.2. Drug Discovery & Disease Modelling
13.25.2.1. Target Identification
13.25.2.2. Target Validation
13.25.2.3. Lead Discovery
13.25.2.4. Lead Optimization
13.25.3. Preclinical Drug Development
13.25.3.1. Pharmacokinetic
13.25.3.2. Pharmacodynamics
13.25.4. Clinical Trials
13.25.4.1. Phase I
13.25.4.2. Phase II
13.25.4.3. Phase III
13.25.5. Human Body Simulation Software
13.26. Rest of Asia Pacific Computational Biology Market Forecast, by End Use
13.26.1. Academics
13.26.2. Industry
13.26.3. Commercial
13.27. Asia Pacific Computational Biology Market Attractiveness Analysis
13.27.1. By Services
13.27.2. By Application
13.27.3. By End Use
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments
14. Middle East & Africa Computational Biology Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Computational Biology Market Overview
14.3. Middle East & Africa Computational Biology Market Value Share Analysis, by Services
14.4. Middle East & Africa Computational Biology Market Forecast, by Services
14.4.1. In-house
14.4.2. Contract
14.5. Middle East & Africa Computational Biology Market Value Share Analysis, by Application
14.6. Middle East & Africa Computational Biology Market Forecast, by Application
14.6.1. Cellular & Biological Simulation
14.6.1.1. Computational Genomics
14.6.1.1.1. Databases
14.6.1.1.2. Infrastructure/Hardware
14.6.1.1.3. Software & Services
14.6.1.2. Computational Proteomics
14.6.1.3. Pharmacogenomics
14.6.1.4. Others (Transcriptomics/ Metabolomics)
14.6.2. Drug Discovery & Disease Modelling
14.6.2.1. Target Identification
14.6.2.2. Target Validation
14.6.2.3. Lead Discovery
14.6.2.4. Lead Optimization
14.6.3. Preclinical Drug Development
14.6.3.1. Pharmacokinetic
14.6.3.2. Pharmacodynamics
14.6.4. Clinical Trials
14.6.4.1. Phase I
14.6.4.2. Phase II
14.6.4.3. Phase III
14.6.5. Human Body Simulation Software
14.7. Middle East & Africa Computational Biology Market Value Share Analysis, by End Use
14.8. Middle East & Africa Computational Biology Market Forecast, by End Use
14.8.1. Academics
14.8.2. Industry
14.8.3. Commercial
14.9. Middle East & Africa Computational Biology Market Value Share Analysis, by Country
14.10. Middle East & Africa Computational Biology Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Computational Biology Market Analysis, by Country
14.12. GCC Computational Biology Market Forecast, by Services
14.12.1. In-house
14.12.2. Contract
14.13. GCC Computational Biology Market Forecast, by Application
14.13.1. Cellular & Biological Simulation
14.13.1.1. Computational Genomics
14.13.1.1.1. Databases
14.13.1.1.2. Infrastructure/Hardware
14.13.1.1.3. Software & Services
14.13.1.2. Computational Proteomics
14.13.1.3. Pharmacogenomics
14.13.1.4. Others (Transcriptomics/ Metabolomics)
14.13.2. Drug Discovery & Disease Modelling
14.13.2.1. Target Identification
14.13.2.2. Target Validation
14.13.2.3. Lead Discovery
14.13.2.4. Lead Optimization
14.13.3. Preclinical Drug Development
14.13.3.1. Pharmacokinetic
14.13.3.2. Pharmacodynamics
14.13.4. Clinical Trials
14.13.4.1. Phase I
14.13.4.2. Phase II
14.13.4.3. Phase III
14.13.5. Human Body Simulation Software
14.14. GCC Computational Biology Market Forecast, by End Use
14.14.1. Academics
14.14.2. Industry
14.14.3. Commercial
14.15. South Africa Computational Biology Market Forecast, by Services
14.15.1. In-house
14.15.2. Contract
14.16. South Africa Computational Biology Market Forecast, by Application
14.16.1. Cellular & Biological Simulation
14.16.1.1. Computational Genomics
14.16.1.1.1. Databases
14.16.1.1.2. Infrastructure/Hardware
14.16.1.1.3. Software & Services
14.16.1.2. Computational Proteomics
14.16.1.3. Pharmacogenomics
14.16.1.4. Others (Transcriptomics/ Metabolomics)
14.16.2. Drug Discovery & Disease Modelling
14.16.2.1. Target Identification
14.16.2.2. Target Validation
14.16.2.3. Lead Discovery
14.16.2.4. Lead Optimization
14.16.3. Preclinical Drug Development
14.16.3.1. Pharmacokinetic
14.16.3.2. Pharmacodynamics
14.16.4. Clinical Trials
14.16.4.1. Phase I
14.16.4.2. Phase II
14.16.4.3. Phase III
14.16.5. Human Body Simulation Software
14.17. South Africa Computational Biology Market Forecast, by End Use
14.17.1. Academics
14.17.2. Industry
14.17.3. Commercial
14.18. Rest of Middle East & Africa Computational Biology Market Forecast, by Services
14.18.1. In-house
14.18.2. Contract
14.19. Rest of Middle East & Africa Computational Biology Market Forecast, by Application
14.19.1. Cellular & Biological Simulation
14.19.1.1. Computational Genomics
14.19.1.1.1. Databases
14.19.1.1.2. Infrastructure/Hardware
14.19.1.1.3. Software & Services
14.19.1.2. Computational Proteomics
14.19.1.3. Pharmacogenomics
14.19.1.4. Others (Transcriptomics/ Metabolomics)
14.19.2. Drug Discovery & Disease Modelling
14.19.2.1. Target Identification
14.19.2.2. Target Validation
14.19.2.3. Lead Discovery
14.19.2.4. Lead Optimization
14.19.3. Preclinical Drug Development
14.19.3.1. Pharmacokinetic
14.19.3.2. Pharmacodynamics
14.19.4. Clinical Trials
14.19.4.1. Phase I
14.19.4.2. Phase II
14.19.4.3. Phase III
14.19.5. Human Body Simulation Software
14.20. Rest of Middle East & Africa Computational Biology Market Forecast, by End Use
14.20.1. Academics
14.20.2. Industry
14.20.3. Commercial
14.21. Middle East & Africa Computational Biology Market Attractiveness Analysis
14.21.1. By Services
14.21.2. By Application
14.21.3. By End Use
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments
15. South America Computational Biology Market Analysis
15.1. Key Findings
15.2. South America Computational Biology Market Overview
15.3. South America Computational Biology Market Value Share Analysis, by Services
15.4. South America Computational Biology Market Forecast, by Services
15.4.1. In-house
15.4.2. Contract
15.5. South America Computational Biology Market Value Share Analysis, by Application
15.6. South America Computational Biology Market Forecast, by Application
15.6.1. Cellular & Biological Simulation
15.6.1.1. Computational Genomics
15.6.1.1.1. Databases
15.6.1.1.2. Infrastructure/Hardware
15.6.1.1.3. Software & Services
15.6.1.2. Computational Proteomics
15.6.1.3. Pharmacogenomics
15.6.1.4. Others (Transcriptomics/ Metabolomics)
15.6.2. Drug Discovery & Disease Modelling
15.6.2.1. Target Identification
15.6.2.2. Target Validation
15.6.2.3. Lead Discovery
15.6.2.4. Lead Optimization
15.6.3. Preclinical Drug Development
15.6.3.1. Pharmacokinetic
15.6.3.2. Pharmacodynamics
15.6.4. Clinical Trials
15.6.4.1. Phase I
15.6.4.2. Phase II
15.6.4.3. Phase III
15.6.5. Human Body Simulation Software
15.7. South America Computational Biology Market Value Share Analysis, by End Use
15.8. South America Computational Biology Market Forecast, by End Use
15.8.1. Academics
15.8.2. Industry
15.8.3. Commercial
15.9. South America Computational Biology Market Value Share Analysis, by Country
15.10. South America Computational Biology Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Computational Biology Market Analysis, by Country
15.12. Brazil Computational Biology Market Forecast, by Services
15.12.1. In-house
15.12.2. Contract
15.13. Brazil Computational Biology Market Forecast, by Application
15.13.1. Cellular & Biological Simulation
15.13.1.1. Computational Genomics
15.13.1.1.1. Databases
15.13.1.1.2. Infrastructure/Hardware
15.13.1.1.3. Software & Services
15.13.1.2. Computational Proteomics
15.13.1.3. Pharmacogenomics
15.13.1.4. Others (Transcriptomics/ Metabolomics)
15.13.2. Drug Discovery & Disease Modelling
15.13.2.1. Target Identification
15.13.2.2. Target Validation
15.13.2.3. Lead Discovery
15.13.2.4. Lead Optimization
15.13.3. Preclinical Drug Development
15.13.3.1. Pharmacokinetic
15.13.3.2. Pharmacodynamics
15.13.4. Clinical Trials
15.13.4.1. Phase I
15.13.4.2. Phase II
15.13.4.3. Phase III
15.13.5. Human Body Simulation Software
15.14. Brazil Computational Biology Market Forecast, by End Use
15.14.1. Academics
15.14.2. Industry
15.14.3. Commercial
15.15. Mexico Computational Biology Market Forecast, by Services
15.15.1. In-house
15.15.2. Contract
15.16. Mexico Computational Biology Market Forecast, by Application
15.16.1. Cellular & Biological Simulation
15.16.1.1. Computational Genomics
15.16.1.1.1. Databases
15.16.1.1.2. Infrastructure/Hardware
15.16.1.1.3. Software & Services
15.16.1.2. Computational Proteomics
15.16.1.3. Pharmacogenomics
15.16.1.4. Others (Transcriptomics/ Metabolomics)
15.16.2. Drug Discovery & Disease Modelling
15.16.2.1. Target Identification
15.16.2.2. Target Validation
15.16.2.3. Lead Discovery
15.16.2.4. Lead Optimization
15.16.3. Preclinical Drug Development
15.16.3.1. Pharmacokinetic
15.16.3.2. Pharmacodynamics
15.16.4. Clinical Trials
15.16.4.1. Phase I
15.16.4.2. Phase II
15.16.4.3. Phase III
15.16.5. Human Body Simulation Software
15.17. Mexico Computational Biology Market Forecast, by End Use
15.17.1. Academics
15.17.2. Industry
15.17.3. Commercial
15.18. Rest of South America Computational Biology Market Forecast, by Services
15.18.1. In-house
15.18.2. Contract
15.19. Rest of South America Computational Biology Market Forecast, by Application
15.19.1. Cellular & Biological Simulation
15.19.1.1. Computational Genomics
15.19.1.1.1. Databases
15.19.1.1.2. Infrastructure/Hardware
15.19.1.1.3. Software & Services
15.19.1.2. Computational Proteomics
15.19.1.3. Pharmacogenomics
15.19.1.4. Others (Transcriptomics/ Metabolomics)
15.19.2. Drug Discovery & Disease Modelling
15.19.2.1. Target Identification
15.19.2.2. Target Validation
15.19.2.3. Lead Discovery
15.19.2.4. Lead Optimization
15.19.3. Preclinical Drug Development
15.19.3.1. Pharmacokinetic
15.19.3.2. Pharmacodynamics
15.19.4. Clinical Trials
15.19.4.1. Phase I
15.19.4.2. Phase II
15.19.4.3. Phase III
15.19.5. Human Body Simulation Software
15.20. Rest of South America Computational Biology Market Forecast, by End Use
15.20.1. Academics
15.20.2. Industry
15.20.3. Commercial
15.21. South America Computational Biology Market Attractiveness Analysis
15.21.1. By Services
15.21.2. By Application
15.21.3. By End Use
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments
16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. DassaultSystèmes SE
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Company Footprint
16.3.2. Certara
16.3.3. Chemical Computing Group ULC
16.3.4. Compugen Ltd
16.3.5. Rosa & Co. LLC
16.3.6. Genedata AG
16.3.7. Insilico Biotechnology AG
16.3.8. Leadscope Inc.
16.3.9. Nimbus Discovery LLC
16.3.10. Strand Life Sciences
16.3.11. Schrodinger
16.3.12. Simulation Plus Inc.
16.3.13. Accelrys
16.3.14. Entelos
16.3.15. RhenoviaPharma SA
16.3.16. StemoniXInc
16.3.17. Computational Genomics Laboratory
16.3.18. Elucidata
16.3.19. DNAnexus
16.3.20. Simons Foundation
17. Primary Key Insights